Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia
Tóm tắt
Iron-rich transfusions and/or a compensatory increase in iron absorption ultimately result in iron loading in patients with β-thalassaemia. Hence, without iron chelation, iron accumulates relentlessly. Deferiprone has been shown to be capable of reducing the iron burden in patients with b-thalassaemia. However, there is wide interpatient variation in deferiprone-induced urinary iron excretion (UIE). We hypothesized that splenectomy and iron status might influence the pharmacokinetic profiles of deferiprone in patients with β-thalassaemia/haemoglobin E, and the present study was aimed at examining this hypothesis. Thirty-one patients with β-thalassaemia/haemoglobin E (20 splenecto-mized and 11 non-splenectomized patients) were enrolled in the study. After an overnight fast, the subjects received a single oral dose of deferiprone 25 mg/kg of body weight. Blood samples were collected pre-dosing and at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360 and 480 minutes after dosing. Urine output was pooled and collected at 0–2, 2–4, 4–8, 8–12 and 12–24 hour intervals. Serum and urine concentrations of deferiprone and its metabolite deferiprone glucuronide were determined using a validated high-performance liquid chromatography method. Serum deferiprone-chelated iron and UIE were determined using a validated colourimetric method. No significant difference in the pharmacokinetic parameters of non-conjugated deferiprone was observed between splenectomized and non-splenectomized patients. However, the maximum serum concentration (Cmax) and the area under the serum concentration-time curve (AUC) from time zero to infinity (AUC∞) values of deferiprone glucuronide were significantly lower (both p < 0.05) in splenectomized patients (median 53.2µmol/L and 12 634 µmol · min/L, respectively) than in non-splenectomized patients (median 70.5 µmol/L and 20 601 mmol · min/L, respectively). The Cmax and the AUC from time zero to the time of the last measurable concentration (AUClast) values of serum deferiprone-chelated iron, as well as UIE, were significantly higher (p < 0.001) in splenectomized patients (median values 7.1 µmol/L, 1645 mmol · min/L and 77.1 mmol, respectively) than in non-splenectomized patients (median values 3.1 µmol/L, 545 mmol · min/L and 12.5 µmol, respectively). Urinary excretion of non-conjugated deferiprone and deferiprone glucuronide did not differ between the two groups. Further analyses using multiple linear regressions indicated that the iron profiles (non-transferrin-bound iron and ferritin) were significant predictors of the pharmacokinetic parameters of non-conjugated deferiprone, deferiprone-chelated iron and UIE. In addition, splenectomy status was identified as the strongest predictor of the AUClast of deferiprone-chelated iron and UIE. Both iron and splenectomy status have significant effects on the pharmacokinetics and iron chelation efficacy of deferiprone. A greater degree of iron overload in splenectomized patients results in alterations in pharmacokinetic parameters (the Cmax and AUC) of deferiprone glucuronide and deferiprone-chelated iron, as well as a significant increase in UIE.
Tài liệu tham khảo
Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th ed. Oxford: Blackwell Science, 2001
Fucharoen S, Winichagoon P. Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr Opin Hematol 2000; 7: 106–12
Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001; 79: 704–12
Viprakit V, Lee-Lee C, Chong QT, et al. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009; 90: 435–45
Vichinsky EP. Changing patterns of thalassemia worldwide. Ann N Y Acad Sci 2005; 1054: 18–24
Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia. Hematology Am Soc Hematol Educ Program 2004; 14–34
Olivieri NF. The ß-thalassemias. N Engl J Med 1999; 341: 99–109
Singh S, Epemolu RO, Dobbin PS, et al. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab Dispos 1992; 20: 256–61
Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733–7
Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489–96
Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000; 85: 115–7
Kontoghiorghes GJ, Goddard JG, Bartlett AN, et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990; 48: 255–61
Hoffbrand AV, Al-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295–300
Diav-Citrin O, Atanackovic G, Koren G. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. Ther Drug Monit 1999; 21: 74–81
Jirasomprasert T, Morales NP, Limenta LMG, et al. Pharmaco/ferrokineticrelated pro-oxidant activity of deferiprone in b-thalassemia. Free Radic Res 2009; 43: 485–91
Fucharoen S, Ketvichit P, Pootrakul P, et al. Clinical manifestation of betathalassemia/hemoglobin E disease. J Pediatr Hematol Oncol 2000; 22: 552–7
Angchaisuksiri P, Atichartakarn V, Aryurachai K, et al. Hemostatic and thrombotic markers in patients with hemoglobin E/beta-thalassemia disease. Am J Hematol 2007; 82: 1001–4
Phrommintikul A, Sukonthasarn A, Kanjanavanit R, et al. Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 2006; 92: 1467–72
Aessopos A, Farmakis D, Tsironi M, et al. Hemodynamic assessment of splenomegaly in beta-thalassemia patients undergoing splenectomy. Ann Hematol 2004; 83: 775–8
Graziano JH, Piomelli S, Hilgartner M, et al. Chelation therapy in betathalassemia major: III. The role of splenectomy in achieving iron balance. J Pediatr 1981; 99: 695–9
Fiorelli G, Fargion S, Piperno A, et al. Iron metabolism in thalassemia intermedia. Haematologica 1990; 75 Suppl. 5: 89–95
Seshadri R, Colebatch JH, Fisher R. Urinary iron excretion in thalassaemia after desferrioxamine administration. Arch Dis Child 1974; 49: 195–9
Limenta LM, Jirasomprasert T, Tankanitlert J, et al. UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol 2008; 65: 908–16
Jittangprasert P, Wilairat P, Pootrakul P. Comparison of colorimetry and electrothermal atomic absorption spectroscopy for the quantification of non-transferrin bound iron in human sera. Southeast Asian J Trop Med Public Health 2004; 35: 1039–44
Recommendations for measurement of serum iron in human blood. Br J Haematol 1978; 38: 291–4
Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol 2005; 5: 606–16
Vatanavicharn S, Anuwatanakulchai M, Tuntawiroon M, et al. Iron absorption in patients with beta-thalassaemia/haemoglobin E disease and the effect of splenectomy. Acta Haematol 1983; 69: 414–6
Wasi P, Pravatmuang P. Serum iron in thalassemia and the effect of splenectomy. J Med Assoc Thai 1979; 62: 532–7
Pootrakul P, Rugkiatsakul R, Wasi P. Increased transferrin iron saturation in splenectomized thalassaemic patients. Br J Haematol 1980; 46: 143–5
Pootrakul P, Vongsmasa V, Laongpanich P, et al. Serum ferritin levels in thalassemias and the effect of splenectomy. Acta Haematol 1981; 66: 244–50
Tavazzi D, Duca L, Graziadei G, et al. Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br J Haematol 2001; 112: 48–50
Domenica Cappellini M, Tavazzi D, Duca L, et al. Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in beta-thalassemia intermedia. Transfus Sci 2000; 23: 245–6
Anderson GJ. Non-transferrin-bound iron and cellular toxicity. J Gastroenterol Hepatol 1999; 14: 105–8
Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrinbound-iron by deferiprone: implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 2006; 30: 183–200
Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2000; 23: 185–92
De Feo TM, Fargion S, Duca L, et al. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res 2001; 25: 1494–9
Lee DH, Liu DY, JacobsJr DR, et al. Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care 2006; 29: 1090–5
Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators. Curr Med Chem 2005; 12: 2695–709
Kontoghiorghes GJ, Pattichis K, Neocleous K, et al. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11: 2161–83
Haverfield EV, Weatherall DJ, Graber AY, et al. Pharmacogenomics of deferiprone metabolism [abstract]. Blood 2005; 106(11): Abstract 2703
Benoit-Biancamano MO, Connelly J, Villeneuve L, et al. Deferiprone glucur-onidation by human tissues and recombinant UGT1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos 2009; 37(2): 322–9
Kontoghiorghes GJ, Bartlett AN, Sheppard L, et al. Oral iron chelation therapy with deferiprone: monitoring of biochemical, drug and iron excretion changes. Arzneimittelforschung 1995; 45: 65–9